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In patients with metastatic melanoma, the most effective
chemotherapeutic single agent is DTIC. Response rates to this
drug, often given in combination with tamoxifen, are around
20% (Hill et al, 1984; Mastrangelo et al, 1992). After DTIC
chemotherapy, almost all patients eventually develop progressive
disease. The place of second-line chemotherapy in such patients is
unclear. Low response rates have been reported in small numbers
of DTIC-resistant patients, with combination carboplatin and cyto-
sine arabinoside (Bajetta et al, 1995), and combination vinblastine,
bleomycin and methotrexate (Porcile et al, 1979). In addition,
there are trials of various chemotherapies which included small
numbers of patients who had already received DTIC, and some
of these retreated patients, although the proportion is not clear,
responded (Quagliana et al, 1984; Johnson et al, 1985; Mulder
et al, 1990; Rusciani et al, 1997).
Melanoma response rates of above 40% have been reported for
combination chemotherapy regimens (McClay and McClay,
1996). One of the most widely used is DTIC, BCNU, cisplatin and
tamoxifen (DBPT) – the Dartmouth regimen. Because of reported
high response rates, it has been suggested that this regimen should
be used in preference to the more easily administered and less
toxic DTIC regimen (Reintgen and Saba, 1993; McClay and
McClay, 1994). Yet there is uncertainty as to whether this regimen
is superior to DTIC, because of reported response rates similar to
DTIC (Johnston et al, 1998; Margolin et al, 1998). Furthermore,
recent randomized comparison of the two regimens does not
indicate significantly greater activity for DBPT (Saxman et al,
1999).
If the DBPT regimen is superior to DTIC, then we reasoned that
it might prove effective in a proportion of patients who were
refractory to DTIC therapy, and it might also benefit patients who
had received DTIC treatment previously, and with subsequent
disease progression required further therapy. This approach would
also provide an indirect comparison of the two regimens. In this
trial, we therefore assessed the effect of the DBPT regimen on
patients with metastatic melanoma who had previously received
DTIC. We assessed the effect in two groups of patients: those with
progressive disease refractory to DTIC who were switched
directly to the DBPT regimen, and those who were not immedi-
ately switched to the DBPT regimen. This latter group included
patients who had either previously responded or attained stable
disease with DTIC treatment, or patients who had received DTIC
as adjuvant therapy.
PATIENTS AND METHODS
Eligibility criteria
Thirty-five consecutive patients with histologically or cyto-
logically proven metastatic malignant melanoma with objective
evidence of progressive disease were enrolled in the trial. Other
eligibility criteria included: Eastern Co-operative Oncology Group
(ECOG) performance status of 0–2, white cell count greater than
3.0 ´ 109 L–1, platelet count greater than 100 ´ 109 L–1, normal
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presence of measurable or evaluable disease, and informed
consent. All patients had previously received DTIC chemotherapy.
All but four of the patients had received concomitant tamoxifen
(20 mg day–1) commencing with the first cycle of DTIC and
continuing for 21 days following the last DTIC treatment. Of the
remaining four patients, three had received DTIC and concomitant
hydroxyurea as part of a study assessing the effects of hydroxyurea
on DNA excision-repair during DTIC treatment (Philip et al,
1994). The remaining patient had received DTIC alone. No
patients had received other cytotoxic chemotherapy. Four patients
had received the protein kinase C partial antagonist bryostatin as
part of a trial (Propper et al, 1998) and two patients had received
low dose weekly interferon g (100 mg m–2) as part of an ongoing
trial.
Assessment of disease response and toxicity
Evaluable and measurable disease sites were assessed before
entering the study by physical examination, plain radiography and
computerized tomography and/or magnetic resonance imaging
where appropriate. Patients were reviewed by a physician before
each cycle of chemotherapy, and new signs, symptoms and
performance status (ECOG) documented. Before each cycle of
chemotherapy a full blood count with a differential white cell
count, serum biochemistry and chest X-ray were performed.
Further imaging investigations for the purposes of tumour
measurement were repeated after every two cycles of treatment, or
at the time of suspected disease progression. National Cancer
Institute Common Toxicity Criteria (NCI-CTC) were used to
grade any toxicities.
Standard WHO criteria for objective response assessment were
employed. Partial response was defined as a 50% or greater
reduction in the sum of the products of the largest perpendicular
diameters of all measurable disease sites. Progressive disease was
indicated by a greater than 25% increase in the size of at least
one measurable lesion, or the appearance of a new lesion. Stable
disease was defined as an increase in disease measurements of less
than 25% or a decrease by less than 50%. Patients with progressive
disease were withdrawn from the study.
Drug regimen
The drug regimen was as previously described (Del Prete et al,
1984). Briefly this comprised cisplatin 25 mg m–2 day–1 and DTIC
220 mg m–2 day–1, both on days 1–3, given in three weekly cycles
and BCNU 100 mg m–2 on day 1 of cycles 1, 3 and 6. Tamoxifen
160 mg was given as a loading dose immediately before the first
cycle of chemotherapy and continued at 20 mg day–1 until 3 weeks
after the last.
Statistical analysis
To ensure a low probability of erroneously rejecting a treatment
that is active in 20% of patients, at least 14 patients were treated,
1760 DJ Propper et al
British Journal of Cancer (2000) 82(11), 1759–1763 © 2000 Cancer Research Campaign
Table 1 Details of patients at start of DBPT treatment
Direct switch Delayed switch Statistical
DTIC to DBPT DTIC to DBPT differences
between groups
(P-value)
No. treated 17 18
M/F 5/12 12/6 < 0.03
Age, years 46 54 NS
(29–81) (35–72)
Performance status 0 0 NS
(0–3) (0–3)
Time since 22 days 285 days < 0.0001
stopping DTIC (20–41) (50–1240)
Previous response to DTIC NS
PD 17 4
SD 4
PR 1
Adjuvant 9
No. of previous cycles of DTIC < 0.001
12 1
27 2
38 2
4 12
5 1
Site of disease NS
Lymph node 4 8
Skin/muscle 11 6
Lung 7 12
Liver 3 4
Intra-abdominal 2 3
Bone 2 4
Stage of disease: all stage IV: NS
Confined to skin/lymph nodes 4 2
Beyond skin/lymph nodes 13 16
Median and range values shown. PD: progressive disease; SD: stable disease; PR: partial response. NS: not significantaccording to previously described principles (Gehan, 1961).
Survival analysis by Kaplan–Meier survival curves were
compared using log-rank tests. All other data where time was a
variable were compared by two-sample Wilcoxon rank-sum tests.
Categorical data were compared by c2 tests. P-values ≤ 0.05 were
considered significant.
RESULTS
Thirty-five patients with progressive metastatic malignant
melanoma previously treated with DTIC were enrolled into the
study. Their previous treatment details and characteristics are
shown in Table 1. Overall there were two PRs and five SDs,
suggesting the regimen is of low efficacy as a second-line treat-
ment. In order to examine this further, the patients were analysed
in two groups. The first group comprised patients who were
switched directly from DTIC treatment to the DBPT regimen
because of progressive disease refractory to DTIC. All these
patients had received DTIC with tamoxifen. The median time
since stopping DTIC was 22 days (range 20–41 days). There were
no responses to the DBPT regimen (Table 2); 16 patients had PD,
and one attained SD for 5 months. This latter patient had slow
growing disease confined to the skin before commencing the
DBPT regimen. The median number of courses of DBPT
chemotherapy given was 2.5 (range 1–4) and the median survival
from the time of commencing DBPT chemotherapy was 109 days
(Table 2).
The second group comprised 18 patients who were not immedi-
ately changed from DTIC chemotherapy to the DBPT regimen
(Table 1). Fourteen of these 18 patients had received tamoxifen at
the time of initial DTIC therapy. This group included patients who
had either attained a PR (one patient) or attained SD (four patients)
with initial DTIC treatment, or received DTIC as adjuvant therapy
(nine patients) or had PD with DTIC and then received other
biological treatments (four patients). The median time since stop-
ping DTIC was 285 days (range 50–1240). In response to DBPT,
two patients, who had received DTIC (and tamoxifen) in the adju-
vant setting, attained PRs (4.5 and 7 months), and four patients
attained SD (4, 5, 6 and 6 months). Of these latter four patients,
one had received DTIC as adjuvant therapy, one had attained SD
and two had PD in response to DTIC. The remaining 12 patients
had PD in response to DBPT (Table 2). Of the four patients who
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Table 2 Responses to DBPT treatment
Direct switch Delayed switch Statistical
DTIC to DBPT DTIC to DBPT difference
between groups
(P-value)
No. treated  17 18
Response to DBPT NS
CR 0 0
PR 0 2 (4.5 and 7 months)
SD 1 4
(5 months) (4, 5, 6 and 6 months)
PD 16 12
Median no of response to (range) 2.5 4 NS
(1–4) (1–6)
Median time to DBPT  44 days 92 days NS
treatment failure 95% CI 42–75 95% CI 39–118
Median survival 109 days 143 days NS
from commencing DBPT 95% CI 78–234 95% CI 127–223
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease. CI = confidence intervals.
Table 3 Survival data from first presentation of melanoma and from commencing DTIC treatment
Direct switch Delayed switch DTIC Statistical
DTIC to DBPT to DBPT difference
between
groups
(p value)
No. treated 17 18
Survival from primary 1.6 2.8 NS
diagnosis (years) (0.4–2.5) (0.7–8.8)
Relapse free survival from 1 1.3 NS
primary diagnosis (years) (0.3–21) (0.2–6)
Survival from commencing 0.5 1.4 < 0.0001
DTIC all patients (years) (0.2–2) (0.6–4.3)
Survival from commencing 0.5 1.5 < 0.0004
non-adjuvant DTIC (years) (0.2–2) (0.9–4.2)
Median and range values shown. Data compared for all patients and (bottom line) for patients who received DTIC for metastatic
disease = 17 patients in direct switch group, and nine patients in delayed switch group.had not received tamoxifen at the time of initial DTIC treatment,
one patient had SD and three PD in response to DBPT. The median
number of DBPT courses given was 4 (range 1–6). Median
survival was 143 days from commencing DBPT treatment
(Table 2).
The two groups were compared to each other to determine
whether there were any differences in prognostic factors, either at
presentation or at the start of DBPT chemotherapy, and for differ-
ences in response or survival. Apart from there being a predomi-
nance of females in the direct switch group (P < 0.03; Table 1)
there were no differences in prognostic factors, either at primary
presentation or at the time of commencing DBPT chemotherapy
(Table 1). The time since stopping DTIC treatment was signifi-
cantly longer in the delayed switch group, reflecting the selection
criteria for the two groups (Table 1). There were no significant
differences between the two groups in survival from starting
DBPT (Table 2) or in survival from primary diagnosis (Table 3).
Excluding the nine patients who received DTIC as adjuvant and
comparing the survival of patients who received DTIC for
metastatic disease, survival from commencing DTIC was signifi-
cantly longer in the delayed switch group (P < 0.0004, Table 3 and
Figure 1), than in the directly switched group.
In general the chemotherapy was well tolerated. The significant
toxicities were neutropenia: > CTC grade 2 in four patients;
thrombocytopenia: > CTC grade 2 in two patients and nausea and
vomiting: > CTC grade 2 in three patients (Table 4).
DISCUSSION
The overall response rate of the 35 patients to DBPT was low, with
two patients attaining PRs, and five SD. This suggests that the
DBPT regimen is not an effective second-line therapy for DTIC
resistant disease. In order to examine further whether this was the
case, the patients were analysed in two groups: those with disease
refractory to DTIC who were directly changed to the DBPT
regimen, and those who were not. There were no responses in the
directly switched group and only one patient attained short-lived
disease stabilization. Thus no patients with de novo DTIC resis-
tance were sensitive to the combination regimen. The implications
of the study for this group of patients are clear. The DBPT regimen
is unlikely to benefit patients whose disease is refractory to DTIC
therapy.
The group whose switch to DBPT was delayed were more
heterogeneous than the directly switched group. It included five
patients who had attained a response or disease stabilization with
DTIC, patients who had not responded to DTIC in the past, but
because of the slow pace of disease had not changed directly to
combination therapy, and patients who had received adjuvant
DTIC. Two patients attained short-lived PRs and four patients
attained SD in response to DBPT. Although this suggests that the
DBPT regimen may have a place for such patients, overall survival
from commencing DBPT was no different from the directly
switched group.
The survival from the time of receiving DTIC for metastatic
disease was significantly longer in patients in the delayed switch
group than in the directly switched group. This group was likely to
have had differences in tumour biology compared to the directly
switched group, since they responded or developed stable
disease with DTIC treatment and/or had more indolent disease.
Nonetheless, there were no conventional prognostic features to
distinguish the groups. In the delayed switch group there were
patients with tumours that were primarily refractory to DTIC, as in
the first group, and those that were not. Mechanisms producing
primary resistance to DTIC may differ from those associated with
later emergence of resistance. Tests to identify patients with non-
refractory disease and the mechanisms of drug resistance would be
useful. DTIC is presumed to exert cytotoxic effects by guanine
methylation, hence possible factors include differences in DNA
repair mechanisms, both for O6-methyl guanine and DTIC induced
DNA strandbreaks, for which we and others have found evidence
for variability in melanoma (Lee et al, 1991; Saunders et al, 1997;
Houlbrook et al, 1998).
There are few studies of patients with metastatic melanoma
receiving second-line chemotherapy with conventional cytotoxic
agents (Everall and Dowd, 1979; Porcile et al, 1979; Quagliana et
al, 1984; Johnson et al, 1985; Mulder et al, 1990; Bajetta et al,
1995; Rusciani et al, 1997). These have generally been phase II
studies of heterogeneous groups of patients, only some of whom
had previously received DTIC. With one exception, we were
unable to find any studies containing comparable numbers of
patients to those reported here. In that study, patients refractory to
cisplatin and tamoxifen were changed to the DBPT regimen. There
were no responses in the 12 patients treated in this way (McClay et
al, 1993b). The same group showed that synergy between tamox-
ifen and cisplatin was lost if melanoma cells had previously been
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Figure 1: Survival probability from commencing DTIC for metastatic
disease. Kaplan–Meier survival curves shown from start of DTIC therapy.
Data shown only for patients who received DTIC as initial therapy for
metastatic disease = 17 in direct switch group and 9 in delayed switch group.
Survival compared by Logrank tests
Table 4 NCI-CTC toxicities associated with DBPT regimen
No. of patients affected
Toxicity Grade 3 Grade 4
Neutropenia 3 1
Thrombocytopenia 2 0
Nausea/vomiting 3 0
Alopecia 0 1
Fatigue 1 0
Neuropathy 1 0
Infection 1 0
Toxicities > grade 2 shown for patients in both groups.exposed and developed resistance to tamoxifen (McClay et al,
1993a). All but four patients in the current study had previously
received tamoxifen before receiving cisplatin in the DBPT
regimen. It is therefore possible that this affected any potential in
vivo synergy between tamoxifen and cisplatin. It is conceivable
that this contributed to the low response rate to DBPT, although
both patients that responded to DBPT had previously received
tamoxifen.
In melanoma, the response rate to the DBPT combination
regimen is reported to exceed 40% (McClay and McClay, 1996).
The response rate to DTIC is around 20% (Mastrangelo et al,
1992). Hence it has been proposed that DBPT or similar combina-
tion regimens are preferable to single-agent DTIC (Reintgen and
Saba, 1993; McClay and McClay, 1994). Nonetheless, others
reported response rates to DBPT comparable to DTIC (Johnston
et al, 1998; Margolin et al, 1998). Recent results of randomized
comparison of DTIC to DBPT indicate no significant differences
in response rate or survival between the two regimens (Saxman et
al, 1999). Differing patient populations could explain the differ-
ences in response rates to DBPT outlined above. Furthermore, it is
not apparent that higher response rates in metastatic melanoma
translate to better symptom palliation or survival (Dorval et al,
1999).
The approach used in this study was, once resistance had been
demonstrated to single-agent therapy then drugs which are postu-
lated to synergize with that agent were added to the treatment
regimen. The study provided similar results to the randomized
comparison of DTIC versus DBPT (Saxman et al, 1999). This
approach represents a rapid way of assessing for possible drug
synergy and/or cross-resistance before or in parallel with
randomized trials.
In conclusion, in patients with progressive metastatic melanoma
that is refractory to DTIC treatment, there appears to be no advan-
tage in changing to the DBPT regimen. If patients are to be consid-
ered for second-line treatment, identifying patterns of in vitro
cross-resistance using newly developed cellular chemosensitivity
assays (Cree and Kurbacher, 1997) may suggest other therapeutic
possibilities. In patients who have had responses to DTIC or the
disease is less aggressive, resistance mechanisms may differ, and
there may be a place for combination chemotherapy.
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